RA Capital Management L.P. Has $532,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

RA Capital Management L.P. lessened its position in Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) by 56.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 336,843 shares of the biopharmaceutical company's stock after selling 429,991 shares during the period. RA Capital Management L.P. owned about 0.51% of Regulus Therapeutics worth $532,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Barclays PLC boosted its holdings in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock worth $132,000 after purchasing an additional 62,549 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Regulus Therapeutics by 193.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock worth $124,000 after buying an additional 52,059 shares during the last quarter. State Street Corp grew its holdings in Regulus Therapeutics by 3.5% in the 3rd quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company's stock valued at $1,572,000 after buying an additional 33,496 shares during the period. Jane Street Group LLC acquired a new position in shares of Regulus Therapeutics during the 3rd quarter valued at about $46,000. Finally, PEAK6 LLC purchased a new position in shares of Regulus Therapeutics during the 4th quarter worth about $95,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Regulus Therapeutics Stock Performance

RGLS stock remained flat at $7.85 on Friday. 3,074,685 shares of the company traded hands, compared to its average volume of 869,941. The firm has a market cap of $520.01 million, a PE ratio of -7.34 and a beta of 1.03. Regulus Therapeutics Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $8.20. The stock's fifty day moving average is $2.11 and its two-hundred day moving average is $1.66.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). During the same quarter in the previous year, the business earned ($0.40) EPS. On average, equities analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

RGLS has been the topic of a number of research reports. Leerink Partners restated a "market perform" rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a report on Wednesday. Wells Fargo & Company reissued an "equal weight" rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a research report on Thursday. Leerink Partnrs cut shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday. Jones Trading reissued a "hold" rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday. Finally, Canaccord Genuity Group reaffirmed a "hold" rating and issued a $11.00 target price (down previously from $28.00) on shares of Regulus Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $8.50.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.